ModifiedPremera BluecrossPolicy N/A

Rituximab products (Riabni, Ruxience, Truxima, Rituxan) for non-oncologic indications and site-of-service review

Defines medical necessity criteria, site-of-service requirements, and coverage stance for rituximab and specified biosimilars for a range of autoimmune, hematologic, and related non-oncologic conditions; applies to Premera members (with a noted Alaska exception for SOS criteria).

Policy Summary

PayerPremera Bluecross

PolicyRituximab products (Riabni, Ruxience, Truxima, Rituxan) for non-oncologic indications and site-of-service review

Policy CodePolicy N/A

Change TypeFormulary preference & step therapy updatesSOS exception added

Effective DateJan 2, 2026

Next Review DateN/A

Key ActionObtain prior authorization and document trial and failure of preferred rituximab biosimilars (e.g., Ruxience or Truxima) before requesting non-preferred Rituxan/Rituxan Hycela.

SourceLink

POLICY UPDATE CHANGES

Changed Ruxience (rituximab-pvvr) to a preferred product and moved Rituxan and Rituxan Hycela to non-preferred products.

Updated preferred/non-preferred status for multiple adalimumab products used in step therapy for rheumatoid arthritis.

Added exception to site-of-service requirements for certain individuals receiving treatment for cytokine release syndrome (CRS).

Updated Riabni (rituximab-arrx) and other biosimilar preferred/non-preferred statuses, including Avsola and Tocilizumab product adjustments in criteria.

Site of Service Medical Necessity criteria does not apply to Alaska fully-insured members pursuant to Alaska HB 226.

Humira (adalimumab) [NDCs starting with 00074] was removed as a first-line step therapy option for the rheumatoid arthritis criteria.

Multiple formulary preference changes for adalimumab, rituximab, infliximab, and tocilizumab products were updated (preferences and required trials adjusted).

Changed Ruxience (rituximab-pvvr) to a preferred product and changed Rituxan (rituximab) and Rituxan Hycela (rituximab and hyaluronidase human) to non-preferred products.

Updated coverage criteria for Riabni (rituximab-arrx), Rituxan, and Rituxan Hycela to require the individual has had an adequate trial and failure with Ruxience or Truxima.

Added the biosimilars Truxima, Ruxience, and Riabni at different preferred/non-preferred tiers and added supporting HCPCS/Q-codes.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

>20distinct non-oncologic indications listed as covered or conditionally covered

12typical maximum approval period

≥13SOS review age threshold

2025product preference updates (recent)

Black boxserious safety risks noted

Coverage Criteria and Indication-Specific Rules

Evidence-supported indications

Rituximab is covered when evidence demonstrates meaningful improvement for specific conditions (examples below):

Rheumatoid arthritis (FDA-labeled): For moderately to severely active RA with inadequate response to one or more standard agents (e.g., TNF inhibitors or methotrexate), rituximab with methotrexate improves disease-related outcomes compared with methotrexate aloneinadequate response to one or more standard agents

evidence: RCTs and observational studies

ANCA-associated vasculitides (GPA, MPA): Rituximab with glucocorticoids is noninferior to cyclophosphamide for induction and may be superior for some maintenance comparisons; evidence includes RCTs demonstrating benefitsevere or relapsing disease per trial populations

evidence: RCTs

Pemphigus and selected pemphigoid diseases: Rituximab plus short-term corticosteroids showed better outcomes than long-term corticosteroids in pemphigus; case series support use in refractory pemphigoid diseasestreatment-refractory or as per RCT in newly diagnosed pemphigus

evidence: RCT and case series

Autoimmune hemolytic anemia (warm AIHA, CAD): For warm AIHA and cold agglutinin syndrome refractory to first-line therapy, rituximab showed improved response rates in RCTs and observational studiesrefractory to first-line therapy

evidence: RCTs

Thrombotic thrombocytopenic purpura (relapsed/refractory): For relapsed or refractory TTP, rituximab demonstrated improved outcomes (lower relapse rates) in nonrandomized and cohort studiesrefractory to plasma exchange and steroids

evidence: phase 2 trial and cohort studies

Factor inhibitors in hemophilia (refractory): For congenital or acquired hemophilia A with inhibitors refractory to first-line therapy, rituximab has shown response rates (25%-50%) in phase 2, cohort, and case seriesrefractory to first-line inhibitor eradication

evidence: phase 2 and cohort studies

Investigational / not covered

Rituximab is considered investigational (not medically necessary) for all non-oncologic uses not specifically outlined as covered in this policy:

Investigational uses: Rituximab is investigational for all other non-oncologic uses not outlined in this policy, including but not limited to induction immunosuppression for kidney or heart transplantation, mixed connective tissue disease, multiple sclerosis, paroxysmal cold hemoglobinuria, prophylaxis for GVHD, treatment of antibody-mediated rejection after pancreatic islet transplantation or in other solid organ transplant recipients, minimal change disease, myasthenia gravis, and others listednot applicable

All other uses not outlined are considered investigational

Factor inhibitor hemophilia A

Factor VIII inhibitor hemophilia A (congenital or acquired) — Covered when ALL of the following are met:

Factor inhibitor hemophilia A: Rituximab considered for individuals with congenital or acquired hemophilia A with inhibitory antibodies refractory to first-line therapy; evidence (phase 2, cohort, case series) shows response rates of approximately 25%–50% with generally high remission rates but with reported treatment-related adverse eventsrefractory to first-line therapy

Evidence judged sufficient to improve net health outcome

Multicentric Castleman disease

Multicentric Castleman disease (MCD) — Covered when the following is met:

Multicentric Castleman disease: Rituximab for multicentric Castleman disease is supported by prospective and retrospective cohort studies demonstrating improved overall survival and reduced incidence of non-Hodgkin lymphomaclinical diagnosis of multicentric Castleman disease

Evidence sufficient to determine meaningful improvement

HCV-associated cryoglobulinemic vasculitis

HCV-associated mixed cryoglobulinemic vasculitis — Covered when ALL of the following are met:

HCV-associated cryoglobulinemic vasculitis: For patients who do not achieve sustained virologic response with antiviral therapy, rituximab may be used as add-on therapy for active diseaserefractory to antiviral therapy or no sustained viral response

Evidence includes RCTs and phase 2 trials showing response consistent with improved outcomes

Neuromyelitis optica (NMO)

Neuromyelitis optica (relapse prevention) — Covered when ALL of the following are met:

NMO relapse prevention: For individuals with neuromyelitis optica refractory to or intolerant of first-line immunosuppression, rituximab may be used for relapse prevention; observational studies and systematic reviews report reduced relapse rates and disability scores after rituximab initiationrefractory to or intolerant of first-line therapy

Evidence considered sufficient

Idiopathic membranous nephropathy

Idiopathic membranous nephropathy — Covered when ALL of the following are met:

Idiopathic membranous nephropathy: Rituximab may be considered for patients who have failed prior immunosuppressive regimens or for patients with moderate risk of progression without prior immunosuppression; evidence includes an RCT and observational studies though additional long-term RCT data are desirablefailed prior immunosuppressive therapy or moderate risk of progression

Evidence judged sufficient to determine meaningful improvement

Steroid-refractory chronic GVHD

Glucocorticoid-refractory chronic graft-versus-host disease (GVHD) — Covered when ALL of the following are met:

Steroid-refractory chronic GVHD: For corticosteroid-refractory chronic GVHD, rituximab is considered medically necessary based on cohort studies demonstrating response in most patients with sustained responses and steroid reduction or discontinuation in some patientscorticosteroid-refractory chronic GVHD

Evidence sufficient to determine meaningful improvement

HLA desensitization (kidney transplant)

Pretransplant HLA desensitization in kidney transplantation — Covered when ALL of the following are met:

HLA desensitization for kidney transplant candidates: Rituximab may be used as part of desensitization protocols for HLA-sensitized renal transplant candidates prior to transplantation; cohort studies demonstrate improved patient and graft survival at 3 years with rituximab-containing regimensHLA-sensitized candidate undergoing desensitization protocol

Covered indication based on cohort evidence

Induction immunosuppression (kidney and heart)

Induction immunosuppression (kidney and heart) — Coverage context and evidence summary:

Induction immunosuppression with rituximab: Rituximab may be considered as part of combination induction regimens for selected kidney transplant candidates based on cohort data; for heart transplant candidates evidence is more limited (consensus and case reports)consideration as part of combination induction regimen

Data limited; larger RCTs needed

ABMR of solid organs

Antibody-mediated rejection (ABMR) of solid organ transplant — Coverage context and evidence conclusion:

ABMR of solid organ transplant: Use of rituximab for ABMR is supported by cohort studies and case series suggesting potential benefit, but evidence is retrospective or small and insufficient to conclusively determine improved health outcomesdiagnosed ABMR refractory to standard therapy

Evidence insufficient; consider investigational unless additional supporting data

Insufficient evidence indications

Examples of indications for which evidence is insufficient to determine net health benefit (use generally considered not medically necessary or investigational unless specific supporting data are provided):

Primary Sjögren syndrome: RCTs and observational studies show inconsistent efficacy; evidence insufficient to determine effects on health outcomesrefractory to first-line therapy

Systemic lupus erythematosus: A large RCT failed to show improved 1-year response; cohort data inconsistent — evidence insufficientrefractory to first-line therapy

Lupus nephritis: Single RCT did not show improved 1-year response; noncomparative studies report modest responses — evidence insufficientrefractory to first-line therapy

Guideline-based recommended uses and sequencing

Guideline and society recommendations relevant to rituximab use and sequencing (summarized positions):

Rheumatoid arthritis sequencing: Rituximab recommended as an option to add or switch for moderate-to-high RA after inadequate MTX, and as an option after TNF inhibitor failure; reassess at ~6 months due to delayed peak effectclinical activity criteria (e.g., CDAI, DAS28)

ACR guidance

Lupus nephritis salvage use: Rituximab may be used for nephritis that fails to improve or worsens after 6 months of induction therapy or after failure of cyclophosphamide and mycophenolatefailure after defined induction durations

ACR task force

ITP role: Rituximab suggested for adults with ITP who are corticosteroid-dependent or refractory (≥3 months), as an alternative to splenectomy

Guideline-recommended uses

Examples of guideline-recommended uses where rituximab is an endorsed option:

Neuromyelitis optica: Rituximab recommended as a first-line therapy per Neuromyelitis Optica Study Group consensus

iTTP (immune-mediated TTP): Rituximab suggested as addition to corticosteroids and plasma exchange for acute events, relapses, and prophylaxis in low ADAMTS13 remission states (conditional recommendations)

Membranous nephropathy: Rituximab recommended as one treatment option for patients with membranous nephropathy and at least one risk factor for progression per KDIGO

Pediatric nephrotic syndrome: Rituximab listed among glucocorticoid-sparing agents for frequently relapsing or steroid-dependent disease; ideally initiated when patient in remission on glucocorticoids

Administrative coverage criteria and formulary sequencing

Administrative coverage criteria, site-of-service rules, and formulary sequencing updates:

Site-of-service applicability: Site-of-Service Medical Necessity criteria applies generally but does not apply to Alaska fully-insured members (per Alaska HB 226); exceptions to SOS may apply for certain individuals receiving treatment for cytokine release syndrome (CRS)

Operationalize exemptions per HB 226 and CRS addition

Non-formulary exception authorization: Non-formulary exception review authorizations for drugs listed in this policy may be approved for up to 12 months<=12 months

Document rationale for exception

Step therapy and formulary sequencing: Humira (adalimumab) NDCs starting with 00074 was removed as a first-line step therapy option for RA; preferred/non-preferred statuses of multiple biologic products were updated and trials of preferred rituximab biosimilars (e.g., Ruxience or Truxima) are required before coverage of non-preferred rituximab products (Rituxan, Rituxan Hycela)

Product-Preference Coverage Criteria

Product-preference coverage requirement for non-preferred rituximab products:

Product preference step: Coverage for non-preferred rituximab products (Riabni, Rituxan, Rituxan Hycela) requires prior trial and documented failure with preferred rituximab products (e.g., Ruxience or Truxima)trial and failure documented

Change effective Jan 3, 2025 and as noted in history entries

Referenced Step Therapy and Sequencing

Referenced step-therapy and sequencing relationships from policy history (operational):

Rituximab product sequencing: Coverage of non-preferred rituximab products (Rituxan, Rituxan Hycela) requires documented trial and failure with all preferred rituximab products (e.g., Ruxience, Truxima, and Riabni when listed preferred)trial and failure documented

Effective dates noted in history entries

Adalimumab product sequencing: Certain adalimumab biosimilars are required as first-line step therapy prior to using second-line rituximab products; preferred product lists have been updated and may vary for custom formularies (see policy 5.01.647)trial and failure documented

Humira AbbVie removal and custom formulary exceptions noted in history

This policy does not apply when the member has a lymphoid malignancy (for example, lymphoma, leukemia, multiple myeloma, or Waldenström's macroglobulinemia). Oncology indications and coverage determinations for rituximab and related monoclonal antibodies are addressed under the separate cancer policy 2.03.502.

Rituximab and biosimilar products used for purposes not specifically outlined in this policy are considered investigational. Examples explicitly listed as investigational include induction immunosuppression for kidney or heart transplantation, multiple sclerosis, myasthenia gravis, minimal change disease, prophylaxis for graft‑versus‑host disease, and treatment of antibody‑mediated rejection (ABMR) of solid organs. Site‑of‑Service Medical Necessity rules described in policy apply only to medical benefit reviews and to members as noted in the policy.

For antibody‑mediated rejection (ABMR) following pancreatic islet transplantation, only a case report was identified in the evidence review; cohort and controlled data are lacking. Because the literature is limited to very small or single‑case reports, there is no definitive coverage statement for ABMR after pancreatic islet transplant and the evidence is considered insufficient to determine improved health outcomes.

The National Multiple Sclerosis Society does not list rituximab among its recommended treatments for multiple sclerosis; this position is noted in the policy and may inform coverage considerations for MS indications.

As noted in the policy, the National Multiple Sclerosis Society does not include rituximab among its listed treatments for MS; this statement is recorded twice in the policy history and evidence summary to emphasize the society's position.

A prior reference to a specific Preferred formulary (Formulary ID: 6064; Rx Plan G3) was removed because that formulary reference is no longer available and is not used for current product‑preference determinations.

Oncology indications for rituximab are managed under the separate cancer policy 2.03.502. This policy explicitly distinguishes non‑oncologic coverage criteria from oncology coverage so that hematologic and lymphoid malignancy uses follow the cancer policy's medical necessity review.

Site‑of‑Service Medical Necessity criteria generally apply to reviews for infusion therapies for members aged 13 years and older. However, Site‑of‑Service criteria do not apply to Alaska fully‑insured members pursuant to Alaska HB 226; for those members only the infusion drug medical necessity criteria apply.

Unless an indication is explicitly described as medically necessary in this policy, use of rituximab products for that condition is considered investigational. The policy lists specific examples of investigational uses to clarify that all other non‑oncologic indications not outlined here are treated as not medically necessary.

All other uses of rituximab products for non‑oncologic conditions not outlined in the policy are designated investigational (not medically necessary) unless and until sufficient supporting evidence and indication‑specific criteria are added to the policy.

Several clinical uses were judged to have insufficient evidence to determine net health benefit. Examples include primary Sjögren syndrome, systemic lupus erythematosus, lupus nephritis, systemic sclerosis, eosinophilic granulomatosis with polyangiitis (EGPA/Churg‑Strauss), multiple sclerosis, myasthenia gravis, minimal change disease (broader populations), and antibody‑mediated rejection (ABMR) in some solid‑organ transplant contexts. For these indications the policy regards rituximab as not medically necessary or investigational unless further high‑quality data or specific criteria are available.

The policy documentation states that there is no Medicare national coverage determination (NCD) for rituximab; no specific Medicare NCD is referenced in this section of the policy.

Specific not‑medically‑necessary statements and investigational determinations are organized elsewhere in the policy. This segment summarizes covered versus investigational uses but directs readers to the full policy sections for explicit NMN wording and indication‑specific criteria.

Coding, HCPCS, and NDC Identifiers

Named rituximab productsmixed

Riabni	rituximab-arrx (first-line biosimilar product listed)
Ruxience	rituximab-pvvr (first-line biosimilar product listed)
Truxima	rituximab-abbs (first-line biosimilar product listed)
Rituxan	rituximab (listed as second-line product; includes Rituxan Hycela)

(metadata) group notemixed

No codes listed

Listed HCPCS codesHCPCS

J3590	Unclassified biologics (use to report: Amjevita, Cyltezo, Hyrimoz HCF, Sandoz and Simlandi)
J9311	Injection, rituximab 10 mg and hyaluronidase (Rituxan Hycela)
J9312	Injection, rituximab (Rituxan), 10 mg
Q5115	Injection, rituximab-abbs, biosimilar, (Truxima), 10 mg
Q5119	Injection, rituximab-pvvr, biosimilar, (Ruxience), 10 mg
Q5123	Injection, rituximab-arrx, biosimilar, (Riabni), 10 mg
Q5156	Injection, tocilizumab-anoh (Avtozma), biosimilar, 1 mg (new code effective 10/01/25)

(metadata) group noteHCPCS

No codes listed

Named NDC prefixes and formulary product identifiersNDC

NDCs starting with 55513	Amjevita (preferred Humira biosimilar reference in policy updates)
NDCs starting with 83457	Hyrimoz (Cordavis) reference
NDCs starting with 00074	Humira (adalimumab) (AbbVie) referenced preferred product NDC prefix
NDCs starting with 61314	Hyrimoz (Sandoz) NDC prefix referenced

(metadata) group noteNDC

No codes listed

No explicit codes in this segmentmixed

No codes listed

Rituximab HCPCS/Q-codes and miscellaneous codesHCPCS

J9311	HCPCS code added for rituximab product
J9312	HCPCS code added for rituximab product
J3590	HCPCS miscellaneous biologic code used for certain biosimilars
Q5115	Q-code supporting Truxima
Q5119	Q-code added
Q5123	HCPCS/Q-code effective 09/01/23

(metadata) group noteHCPCS

No codes listed

HCPCS codes mentioned in historyHCPCS

Q5123	HCPC code added (effective 09/01/23 entry references)
Q5156	HCPC code added (new code effective 10/01/25)

(metadata) group noteHCPCS

No codes listed

inv-40: Hospital-based outpatient setting initial period

Initial hospital-based outpatient periodHospital-based outpatient setting considered medically necessary for the initial course of infusion or re-initiation after ≥6 months; applies for the first 90 days

Clinical conditions warranting hospital settingAllowed when patient has increased risk for infusion complications (e.g., symptomatic cardiac arrhythmia, significant respiratory disease with %FVC ≤40%, unstable renal function, difficult/unstable vascular access, acute mental status changes, prior severe anaphylaxis)

Geographic/access criteriaHospital site may be medically necessary when no outpatient infusion center is within 50 miles and no contracted home infusion agency will travel to the home

CRS-specific criterionHospital-based outpatient site considered medically necessary for cytokine release syndrome (CRS) when CRS is grade 3–4 with fever ≥38°C, hypotension requiring vasopressor(s), and hypoxia requiring high-flow oxygen or positive pressure support

Prior Authorization, Step Therapy, and Documentation Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for the rituximab products listed in this policy. Typical initial and re-authorization approvals may be granted for up to 12 months when the drug‑specific coverage criteria are met and documentation shows ongoing clinical benefit.

Initial and re-authorization approvals: up to 12 months (non‑formulary exception reviews and other reviews)

Prior Authorization

Transplant / Desensitization Uses — Prior Authorization and Evidence Note

Prior authorization may be required when rituximab is used as part of transplant-related care (e.g., HLA desensitization protocols, induction immunosuppression for kidney or heart transplant, or treatment of antibody‑mediated rejection). Evidence for some transplant uses is limited and may prompt case‑by‑case review.

Pretransplant HLA desensitization: covered indication but prior auth recommended
Induction immunosuppression for kidney/heart transplant: may require prior authorization and specialty review

Background, Mechanism, and Evidence Summary

Rituximab is a chimeric monoclonal antibody directed against the CD20 antigen on B lymphocytes. It depletes circulating pre‑B and B cells via complement‑dependent and antibody‑dependent cytotoxicity and is used to treat a range of autoimmune and hematologic conditions in which B cells contribute to disease pathophysiology.

This policy does not reference any specific Medicare National Coverage Determination for rituximab; the document states that no Medicare NCD is specified in the policy sections reviewed.

inv-34 (evidence context): Named rituximab products referenced in background evidence discussion

Named rituximab products referenced in background and product lists:

Named rituximab products: Riabni (rituximab-arrx), Ruxience (rituximab-pvvr), Truxima (rituximab-abbs) are listed as first-line/preferred biosimilars; Rituxan (rituximab) and Rituxan Hycela are listed as second-line/non-preferred products per policy lists

Product names and tiering reflected in policy

Definitions and Safety Notes

inv-77: Rituximab (Rituxan) and biosimilars — definition/key examples

DefinitionRituximab (Rituxan) and specified biosimilars are monoclonal antibody therapies that target B cells; policy examples include Riabni (rituximab-arrx), Ruxience (rituximab-pvvr), Truxima (rituximab-abbs), and Rituxan (rituximab)

Examples of biosimilars listedRiabni (rituximab-arrx), Ruxience (rituximab-pvvr), Truxima (rituximab-abbs)

Clinical context noteAlthough used for oncology, this policy addresses non-oncologic uses of Rituxan and its biosimilars

inv-78: Site of Service (SOS) definition

DefinitionSite of Service (SOS) is the location where the drug is administered (e.g., hospital-based outpatient setting, infusion center, physician office, or at home)

Applicability by age

Policy Revision Timeline

2023-09-01HCPCS code effective

HCPCS code Q5123 listed as effective date for rituximab-arrx (operational note recorded in history).

2024-01-03product preference change (effective)

Ruxience (rituximab-pvvr) designated preferred and Rituxan and Rituxan Hycela designated non-preferred; coverage criteria updated to require trial and failure with preferred biosimilars for Riabni, Rituxan, and Rituxan Hycela (effective Jan 3, 2025 per operational notes).

2020-10-01

Policy Summary

PayerPremera Bluecross

PolicyRituximab products (Riabni, Ruxience, Truxima, Rituxan) for non-oncologic indications and site-of-service review

Policy CodePolicy N/A

Change TypeFormulary preference & step therapy updatesSOS exception added

Effective DateJan 2, 2026

Next Review DateN/A

Key ActionObtain prior authorization and document trial and failure of preferred rituximab biosimilars (e.g., Ruxience or Truxima) before requesting non-preferred Rituxan/Rituxan Hycela.

SourceLink

On This Page

Systemic sclerosis: Observational and small trials report improvements but with high adverse-event rates and limited long-term data — evidence insufficientrefractory to first-line therapy

EGPA (Churg-Strauss): Retrospective and case series show high response/remission rates but severe adverse events; evidence insufficientrefractory to conventional immunosuppressants

Multiple sclerosis: RCTs and registry data mixed with limited efficacy in progressive MS; overall evidence insufficientdisease-specific indications

Myasthenia gravis: Observational data suggest benefit (especially anti-MuSK) but few controlled trials and no RCTs — evidence insufficientrefractory or nonrefractory MG contexts

Minimal change disease (broad population): Evidence supports benefit in pediatric frequent-relapse disease but due to risk of severe complications use should be restricted; broader adult/pediatric evidence insufficientchildren with frequent relapses and severe medication-related adverse events

duration ≥3 months

ASH conditional recommendations

ANCA-associated vasculitis induction: Rituximab with glucocorticoids recommended as an option for inducing remission in severe GPA and MPA, particularly when cyclophosphamide is contraindicated or prior exposure existssevere disease or cyclophosphamide contraindication

NICE guidance

TTP acute/refractory management: Rituximab should be considered in acute iTTP with neurologic or cardiac pathology in conjunction with plasma exchange and steroids, for refractory/relapsing disease, and elective therapy when ADAMTS13 <5% in remissionADAMTS13 activity <5% (elective therapy)

BCSH/ISTH guidance

Transplant desensitization/AMR: ISHLT recommends rituximab for desensitization in HLA-sensitized heart transplant candidates (class 2b) and in combination treatments for ABMR (class 2a); not routine for non-sensitized recipientsspecific desensitization/AMR contexts

ISHLT 2022

ILD and systemic autoimmune disease: Rituximab conditionally recommended for systemic autoimmune rheumatic disease–related ILD and progressive cases (low/conditional evidence)moderate–severe impairment or progression despite first-line agents

ATS/ACR statements

Neurologic indications: Rituximab may be more effective than placebo for RRMS MRI/relapse endpoints (moderate/low confidence) and is recommended as first-line for neuromyelitis optica by NMOSD study groupdisease-specific diagnostic criteria

AAN and NMOSD Study Group

Minimal change disease: Rituximab recommended as an option for frequently relapsing or steroid-dependent MCD instead of prednisone alone

ANCA-associated vasculitis: KDIGO recommends glucocorticoids plus rituximab or cyclophosphamide for induction and notes rituximab preference in specified populations

Myasthenia gravis: Rituximab recommended early for MuSK-Ab+ MG and as an option for refractory AChR-Ab+ MG

trial and failure documented

Affects required prior trials and product sequencing

inv-41: Non-formulary exception duration (coding note)

Non-formulary exception maximum durationNon-formulary exception review authorizations for drugs listed in this policy may be approved for up to 12 months

Documentation requirement for exceptionDocumentation should support the exception rationale and requested duration when seeking a non-formulary exception

Operational clarificationOperationalized in 2025 update: non-formulary exception authorizations standardized to a 12-month maximum

inv-42: Site-of-service review age threshold

SOS review age thresholdSite-of-Service medical necessity review applies to individuals age 13 years or older

Alaska exceptionSite-of-Service Medical Necessity criteria does NOT apply to Alaska fully-insured members; infusion drug criteria apply instead (Alaska HB 226)

Definition of site-of-serviceSite of service refers to where the drug is administered (hospital-based outpatient, infusion center, physician office, or home) and is reviewed for ages ≥13

ABMR (antibody‑mediated rejection): evidence limited; prior authorization and careful documentation advised

Prior Authorization

Site‑of‑Service and Prior Authorization

Site‑of‑service reviews apply to several rituximab products. Requests for an outpatient hospital‑based setting should include documentation explaining why infusion cannot be safely or feasibly provided in the physician’s office, patient’s home, or an infusion center. Site‑of‑service criteria do not apply to Alaska fully‑insured members per Alaska HB 226.

Site‑of‑service documentation required when requesting outpatient hospital infusion
If no outpatient infusion center within 50 miles and no contracted home infusion agency will travel, hospital site may be considered medically necessary
Alaska fully‑insured members: site‑of‑service medical necessity criteria do not apply

Denial Risk

Denial Risk — Site‑of‑Service Mismatch

A site‑of‑service mismatch (requesting hospital outpatient when criteria are not met) may lead to denial of the request. Exceptions are limited and specific (e.g., high‑risk clinical conditions or cytokine release syndrome meeting the policy’s criteria).

Denial risk if site‑of‑service criteria not documented or not met
Exception: certain CRS cases and specified clinical risk factors may justify hospital infusion

Denial Risk

Denial Risk — ABMR Evidence Limitations

Evidence for rituximab in antibody‑mediated rejection (ABMR) and some post‑transplant settings is limited (cohort studies, case series, retrospective data). This limitation increases the need for detailed clinical documentation; approvals for ABMR or related indications may be scrutinized.

ABMR evidence: primarily cohort studies and case series — limited RCT data
Careful documentation of rationale and prior therapies recommended to support medical necessity

Documentation Required

Documentation Requirements — What to Submit

Document the clinical rationale thoroughly for all prior authorization requests. Required documentation includes diagnosis, history and physical documenting severity, prior treatments and responses, and, when applicable, justification for the requested site of service.

Required: diagnosis/condition, H&P with severity, prior treatments and outcomes
If requesting hospital outpatient infusion: explain why office, home, or infusion center not appropriate

Step Therapy

Step Therapy — Rheumatoid Arthritis Biologic Sequencing

For rheumatoid arthritis (RA), step‑therapy sequencing has been updated: trials of preferred adalimumab products, preferred infliximab, and preferred tocilizumab products or specified JAK inhibitors are expected before rituximab is used as second‑line therapy. Recent updates changed product preferences and moved some agents between preferred/non‑preferred status.

RA step sequence: trial and failure of a preferred adalimumab product or specified alternatives (etanercept, preferred infliximab, preferred tocilizumab, Xeljanz/Rinvoq) before rituximab
Policy updates (2024–2026) altered preferred/non‑preferred status; check current formulary and member plan exceptions

Step Therapy

Product‑Preference Step Requirement

Product‑preference step requirements apply: non‑preferred rituximab products (e.g., Rituxan, Rituxan Hycela) now require trial and failure of all preferred rituximab products (Ruxience, Truxima, or updated preferred biosimilars) prior to approval.

Non‑preferred rituximab products require documented trial and failure of all preferred rituximab products
Check history and policy history for which rituximab products are preferred (updates effective Jan 2025–Jan 2026)

Step Therapy

Step Therapy — Adalimumab and Rituximab Requirements

Specific step requirements for adalimumab and rituximab: the policy lists preferred adalimumab biosimilars/products that must be tried before certain rituximab products are authorized for RA. Recent removals and reassignments (e.g., Humira removal from first‑line in 2025 updates, changes to Hyrimoz/Cyltezo status) mean providers must confirm which adalimumab products are required for a given member.

Trial of a preferred adalimumab product is often required prior to rituximab for RA — confirm current preferred product list for the member’s plan
Providers should document prior trials, dates, doses, and reasons for failure/intolerance

Documentation Required

Prior Trial Documentation — What Reviewers Expect

Document prior trials of required formulary/preferred agents. Prior trial documentation should include drug name, dates of therapy, dose, duration, and reason for discontinuation or inadequate response.

Include specifics: agent, start/end dates, dose, objective and subjective response, and adverse events leading to discontinuation

Documentation Required

Vaccination and Biologic Therapy — Documentation Note

Vaccination and biologic therapy guidance: document vaccination status per rheumatology guidance (pneumococcal, influenza IM, hepatitis B, HPV, zoster where applicable) and whether vaccines were administered before initiation of biologic/DMARD therapy as recommended by clinical societies.

Record administration of killed/recombinant vaccines prior to starting biologic/DMARD when applicable
If vaccines were not given prior to therapy, document reasons and any vaccinations given while on therapy

SOS medical necessity review applies for individuals aged 13 years and older

Alaska applicabilitySOS criteria do not apply to Alaska fully-insured members; refer to infusion drug medical necessity criteria only

inv-79: Rituximab / Rituxan definition (mechanism)

Mechanism of actionRituximab is a chimeric monoclonal antibody directed against the CD20 surface antigen on pre-B and mature B lymphocytes, inducing lysis via complement-dependent and antibody-dependent mechanisms

Effect on B cellsRituximab reduces peripheral blood and lymphoid tissue B-cell counts, interrupting pathogenic autoimmune processes

Administration routeRituximab is administered by intravenous infusion

inv-80: Key safety warnings (boxed warnings)

Boxed warnings (major)Fatal infusion reactions (often with first infusion), severe mucocutaneous reactions, hepatitis B reactivation (can lead to fulminant hepatitis and death), and progressive multifocal leukoencephalopathy (PML)

Other labeled precautionsTumor lysis syndrome, infections, cardiac arrhythmias/angina, renal toxicity, bowel obstruction/perforation, embryo-fetal toxicity; avoid live vaccines before/during therapy

Common adverse events in RA trialsUpper respiratory infection, nasopharyngitis, urinary tract infection, bronchitis (≥10% in pivotal RA trials)

inv-81: Mixed connective tissue disease (MCTD) definition

DefinitionMixed connective tissue disease (MCTD) is a disorder with overlapping features of SLE, systemic sclerosis, polymyositis/dermatomyositis, and rheumatoid arthritis associated with anti-RNP antibodies

Evidence for rituximabEvidence limited to small case series; insufficient to determine effects on health outcomes for MCTD

inv-82: Neuromyelitis optica (NMO) definition

DefinitionNeuromyelitis optica (NMO) is a rare autoimmune inflammatory disorder that selectively affects the spinal cord and optic nerves, often associated with aquaporin-4 autoantibody and characterized by severe optic neuritis and transverse myelitis

Clinical course/goalsNMO typically has a more severe course than MS; treatment goals include relapse remission, relapse prevention, and symptom relief

Guideline positionNeuromyelitis Optica Study Group recommended rituximab as a first-line treatment option in consensus guidance

inv-83: HLA-sensitized transplant candidate definition

DefinitionHLA-sensitized transplant candidate: a patient with broadly reactive alloantibodies (eg, from prior pregnancy, transfusion, or transplant) identified by elevated panel reactive antibody (PRA), making organ matching and transplantation higher risk

Desensitization contextDesensitization protocols may include rituximab with IVIG and plasmapheresis; cohort studies show improved 3-year patient and graft survival with rituximab-containing regimens

Documentation suggestedClinical justification should document PRA or degree of sensitization and prior desensitization attempts when requesting rituximab for pretransplant desensitization

inv-84: antineutrophil cytoplasmic antibody (ANCA) definition

DefinitionAntineutrophil cytoplasmic antibody (ANCA): autoantibodies associated with vasculitides such as granulomatosis with polyangiitis and microscopic polyangiitis

Clinical relevanceANCA-associated vasculitides are indications for rituximab induction or maintenance in many guideline statements when criteria met

Evidence noteRituximab with glucocorticoids is noninferior to cyclophosphamide for induction and supported by RCTs for ANCA-associated vasculitis

inv-85: Neuromyelitis optica (NMO) duplicate definition entry

DefinitionNeuromyelitis optica (NMO): rare autoimmune disorder affecting optic nerves and spinal cord, often AQP4-Ab positive, causing severe optic neuritis and transverse myelitis

Evidence for rituximabObservational studies and systematic reviews report reduced relapse rates and disability scores after rituximab; evidence supports meaningful improvement for relapse prevention in refractory NMO

Guideline positionConsensus guidance lists rituximab among first-line options for NMO

inv-86: iTTP definition (ISTH conditional recommendation context)

Definition/contextImmune-mediated thrombotic thrombocytopenic purpura (iTTP): a disorder where ISTH guidelines conditionally recommend adding rituximab to plasma exchange and corticosteroids for acute events, relapses, and prophylaxis in low ADAMTS13 remission states

Recommendation detailISTH gives conditional recommendations for rituximab in first acute events, relapses, and in remission with low ADAMTS13 activity based on very low-certainty evidence

Clinical thresholdConsider rituximab electively when ADAMTS13 activity is <5% in remission per guideline context

inv-87: CRS exception (site-of-service)

CRS site-of-service exceptionAn exception to site-of-service requirements was added for certain individuals receiving treatment for cytokine release syndrome (CRS); hospital-based administration is medically necessary when CRS is grade 3–4 with specified physiologic criteria

CRS physiologic criteriaCRS grade 3–4 defined by fever ≥38°C plus hypotension requiring vasopressor(s) and hypoxia requiring high-flow oxygen or positive pressure support

Relation to SOS policyCRS exception operationalized in 2025 update as limited exemption to usual site-of-service rules

inv-88: Biosimilar definition

DefinitionBiosimilar: a biologic product highly similar to an FDA-approved reference rituximab product; policy examples include Truxima, Ruxience, and Riabni

Policy examplesTruxima (rituximab-abbs), Ruxience (rituximab-pvvr), Riabni (rituximab-arrx) are listed as biosimilars in the policy

Regulatory noteBiosimilars are subject to the product's FDA dosage and administration prescribing information as referenced in the history updates

inv-89: preferred product definition

DefinitionPreferred product: a rituximab or related biologic designated on the plan's preferred product list (eg, Ruxience, Truxima, and in history Riabni was changed to preferred) and required to be tried prior to non-preferred products

Policy implicationCoverage of non-preferred rituximab products requires documented trial and failure of preferred products per updated product-preference rules

Effective change noteRuxience was changed to preferred and criteria updated effective Jan 3, 2025 (history entries)

inv-90: non-formulary exception definition

DefinitionNon-formulary exception: an authorization process allowing coverage of non-formulary drugs when clinically justified; authorizations for drugs in this policy may be approved up to 12 months

Documentation for exceptionMedical records must document rationale for exception and support requested duration; documentation should accompany non-formulary exception reviews

Operational noteClarified in 2025 update that non-formulary exception review authorizations may be approved for up to 12 months

HCPCS/Q-code Q5119 added (history entry documenting addition of Q-codes for biosimilars and J3590 usage).

2023-09-01HCPCS code effective

HCPCS code Q5123 noted as effective 09/01/23 and recorded in the policy history.

2025-11-01HCPCS/Q-code addition

HCPCS code Q5156 (tocilizumab-anoh, Avtozma) added (history entry notes Q5156 new code effective 10/01/25 and documented in 11/01/25 history).

2024-07-01step therapy update

Humira (adalimumab) removed as a first-line step therapy option for rheumatoid arthritis in planned policy changes (history notes removal effective 07/01/25 following provider notification).

2024-05-01formulary preference clarification

Preferred adalimumab product list clarified (Humira preferred product details and custom formulary exceptions documented during 2024 reviews).

2025-01-01product-preference operational change

Preferred adalimumab and rituximab biosimilar lists updated with operational effective dates and provider notifications affecting RA biologic sequencing and step therapy requirements.

2025-01-27site-of-service exception (Alaska)Latest

Policy updated to clarify Site-of-Service Medical Necessity criteria does not apply to Alaska fully-insured members per Alaska HB 226 (annual review approved Jan 27, 2025).